Reactome: A Curated Pathway Database
THIS SITE IS USED FOR CURATION AND TESTING
IT IS NOT STABLE, IS LINKED TO AN INCOMPLETE DATA SET, AND IS NOT MONITORED FOR PERFORMANCE. WE STRONGLY RECOMMEND THE USE OF OUR PUBLIC SITE

Query author contributions in Reactome

Reactome depends on collaboration between our curation team and outside experts to assemble and peer-review its pathway modules. The integration of ORCID within Reactome enables us to meet a key challenge with authoring, curating and reviewing biological information by incentivizing and crediting the external experts that contribute their expertise and time to the Reactome curation process. More information is available at ORCID and Reactome.

If you have an ORCID ID that is not listed on this page, please forward this information to us and we will update your Reactome pathway records.

Name Email address

Details on Person Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials

Class:IdLiteratureReference:9660202
_displayNameComparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
_timestamp2019-09-09 14:12:10
author[Person:9660146] Xie, Yifeng
[Person:9660187] Su, Peiling
[Person:9660178] Sun, Yifan
[Person:9660170] Zhang, Hongsheng
[Person:9660126] Zhao, Rong
[Person:5665599] Li, Liang
[Person:9660180] Meng, Lanfen
created[InstanceEdit:9660123] Jassal, Bijay, 2019-09-09
journalBMC Nephrol
pages272
pubMedIdentifier28841848
titleComparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials
volume18
year2017
(literatureReference)[ChemicalDrug:9660179] paricalcitol [nucleoplasm]
[Reaction:9660192] VDR agonists bind VDR [Homo sapiens]
[Change default viewing format]
No pathways have been reviewed or authored by Comparative efficacy and safety of paricalcitol versus vitamin D receptor activators for dialysis patients with secondary hyperparathyroidism: a meta-analysis of randomized controlled trials (9660202)